Ultime notizie per Palatin Techs (AMEX:PTN) Azioni

Palatin Techs

Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Palatin Technologies Inc

PT Bank CIMB Niaga Tbk

PT VALE INDONESIA TBK by PT Vale Indonesia TBK

PT Vale Indonesia Tbk

PT VALE INDONESA UNSP/ADR by PT Vale Indonesia TBK

PT INDO KORDSA TBK by PT INDO KORDSA TBK

Pacer Trendpilot 100 ETF

PARTNER COMMUNS CO ORD by Partner Communications Company Ltd.

Partner Communications Co Ltd

Partner Communications Co Ltd ADR

PLATINA RESOURCES LTD ORD by Platina Resources, Ltd.

Platina Resources Ltd

ParcelPal Logistics Inc

PARCELPAL LOGISTICS INC by PARCELPAL LOGISTICS INC.

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) with a Buy and maintains $17 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Palatin Techs, Maintains $17 Price Target

Biotech

Macro Economic Events

Economics

General

Palatin To Present Preclinical Data From Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program At ObesityWeek 2024

<h3>Gainers</h3>
<ul>
<li>Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) stock moved upwards by 4181.6% to $274.02 during Monday's pre-market session. The market value of their outstanding shares is at $79.8 billion. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock increased by 8.88% to $14.59. The company's market cap stands at $316.7 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 8.07% to $2.41. The market value of their outstanding shares is at $84.1 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock rose 5.0% to $1.26. The company's market cap stands at $24.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares moved upwards by 4.87% to $1.29. The market value of their outstanding shares is at $237.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock fell 14.9% to $0.37 during Monday's pre-market session. The company's market cap stands at $2.6 million. </li>
<li>TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) stock declined by 13.02% to $23.4. The market value of their outstanding shares is at $3.6 billion. As per the press release, Q3 earnings came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 7.64% to $0.06. The market value of their outstanding shares is at $3.4 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock declined by 6.7% to $2.51. The company's market cap stands at $2.8 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) stock declined by 5.23% to $1.45. The company's market cap stands at $61.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CVRX

NKTR

RAPT

RXRX

TGTX

THAR

VERO

VRCA

10 Health Care Stocks Moving In Monday's Pre-Market Session

Palatin Technologies shares are trading higher after the company announced it completed enrollment for its Phase 2 clinical study of Bremelanotide with topline results expected in Q1 of the 2025 calendar year.

Palatin Completes Enrollment In Phase 2 Clinical Study Of Bremelanotide; Topline Results Expected In Q1 Of Calendar Year 2025

<h3>Gainers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares rose 13.7% to $0.06 during Monday's after-market session. The market value of their outstanding shares is at $7.2 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 6.11% to $0.92. The company's market cap stands at $17.8 million. </li>
<li>GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares rose 5.64% to $14.65. The market value of their outstanding shares is at $454.9 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock moved upwards by 5.45% to $0.75. The company's market cap stands at $15.1 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock moved upwards by 4.99% to $0.33. The market value of their outstanding shares is at $2.8 million. </li>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock moved upwards by 4.93% to $9.79. The market value of their outstanding shares is at $485.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares decreased by 8.9% to $1.13 during Monday's after-market session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.8% to $4.14. The company's market cap stands at $5.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock declined by 5.67% to $1.5. The market value of their outstanding shares is at $11.1 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 5.07% to $0.33. The market value of their outstanding shares is at $6.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares decreased by 4.89% to $6.81. The company's market cap stands at $227.2 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 4.89% to $0.78. The company's market cap stands at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AURA

BFRI

CTCX

CUTR

DWTX

GRAL

GRTS

INVO

OGEN

SERA

12 Health Care Stocks Moving In Monday's After-Market Session

Palatin Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Palatin was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide. Section 1003(a)(iii) requires a listed company to have stockholders' equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. Palatin previously reported that it was not in compliance with continued listing standards under Section 1003(a)(i) and (ii).

Palatin Receives Notice Of Non-Compliance From NYSE American

Earnings

Earnings Beats

Palatin Techs Q4 2024 GAAP EPS $(0.51) Beats $(0.56) Estimate, Cash Balance Of $6.5M

<h3>Gainers</h3>
<ul>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 53.5% to $5.15 during Friday's regular session. The company's market cap stands at $3.8 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) stock increased by 31.77% to $0.6. The market value of their outstanding shares is at $29.1 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 22.72% to $1.89. The market value of their outstanding shares is at $11.1 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock moved upwards by 22.69% to $1.19. The market value of their outstanding shares is at $43.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares rose 16.98% to $1.24. The company's market cap stands at $12.6 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares increased by 16.73% to $0.25. The company's market cap stands at $5.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares decreased by 27.0% to $1.49 during Friday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 24.45% to $3.4. The company's market cap stands at $45.3 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares decreased by 21.54% to $0.47. The market value of their outstanding shares is at $3.5 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock declined by 18.43% to $0.77. The company's market cap stands at $14.9 million. </li>
<li>Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares fell 17.41% to $62.49. The company's market cap stands at $5.8 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 15.49% to $2.02. The company's market cap stands at $23.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHC

ESLA

INDP

MYNZ

NVNO

ONCO

PSTV

TOVX

12 Health Care Stocks Moving In Friday's Intraday Session

Health Care

Palatin Technologies Has Started Patient Dosing In Phase 2 Study Of Bremelanotide Co-administered With Tirzepatide For Obesity, Complete Enrollment Is Currently Expected In 3Q 2024, With Topline Data Expected In Q1 Calendar Year 2025

Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M

Palatin Technologies Has Initiated Phase 2 Study Of Bremelanotide, A Melanocortin 4 Receptor, Co-administered With A Phosphodiesterase 5 Inhibitor, For Erectile Dysfunction In Patients That Do Not Respond To PDE5i Monotherapy. Topline Data Is Expected By

<ul>
<li>Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity</li>
<li>Topline data expected by end of calendar year 2024</li>
<li>Additional studies under assessment for multiple metabolic conditions</li>
</ul>

Palatin Begins Phase 2 Trial To Assess Combined Efficacy Of Bremelanotide And Tirzepatide In Obesity Management

Warning: PTN is at high risk of performing badly

Palatin (PTN) has completed enrollment in the study investigating the safety, tolerability, and effectiveness of co-administration of bremelanotide...

Palatin completes enrollment in Phase 2 study of bremelanotide in obesity

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Palatin Technologies (PTN – Research Report), retaining the price target of ...

Palatin Technologies: Promising Pipeline Advances and Positive Trial Developments Drive Buy Rating

Palatin Technologies (PTN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

Palatin Technologies' PL7737: A Promising Obesity Treatment Highlighted by New Preclinical Data

Tired,Teen,Girl,Rubbing,Dry,Irritable,Eyes,Feel,Eye,Strain

Press Releases

FDA Confirms Acceptability of Palatin&#39;s Remaining Phase 3 Pivotal Clinical Trials For PL9643 In Dry Eye Disease (DED)

Screenshot 2024-08-28 at 6.22.42 PM

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory &amp;  Autoimmune Conditions, Obesity And Sexual Dysfunctions

Biochemical,Research,Scientist,Team,Working,With,Microscope,For,Coronavirus,Vaccine

First Patient Dosed In Phase 2 Clinical Study Of Palatin&#39;s Bremelanotide Co-Administered With Tirzepatide (GLP-1) For The Treatment Of Obesity

Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development – Targeting Inflammatory &  Autoimmune Conditions, Obesity And Sexual Dysfunctions

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Comments

Palatin Techs

Notizie

Ultime notizie per Palatin Techs (AMEX:PTN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO